%PDF-1.4
%
57 0 obj
<>
endobj
54 0 obj
<>
endobj
107 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-02-02T14:41:26Z
2024-03-28T01:26:04-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T01:26:04-07:00
application/pdf
Heather
2003-984.mar
uuid:b41f1557-1dd1-11b2-0a00-fd09275d6100
uuid:b41f1559-1dd1-11b2-0a00-aa0000000000
endstream
endobj
43 0 obj
<>
endobj
44 0 obj
<>
endobj
58 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
125 0 obj
[129 0 R]
endobj
126 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 53.8216 56.7343 Tm
(434)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:3)Tj
/T1_1 1 Tf
-43.8117 85.0369 Td
(Rheumatology preliminary core set of disease activity measures for)Tj
0 -1.25 TD
[(rheumatoid arthritis clinical trials. )17.7 (The Committee on Outcome)]TJ
T*
[(Measures in Rheumatoid )54.8 (Arthritis Clinical )17.7 (T)35 (rials. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1993;36:729-40.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Fried BJ, Boers M, Baker PR. )54.8 (A)-220.1 (method for achieving consensus on)]TJ
2.1381 -1.25 Td
[(rheumatoid arthritis outcome measures: the OMERACT)-257.3 (conference)]TJ
T*
(process. J Rheumatol 1993;20:548-51.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Felson DT)73.9 (, )54.8 (Anderson JJ, Boers M, et al. )54.8 (American College of)]TJ
2.175 -1.25 Td
[(Rheumatology)64.9 (. Preliminary definition of improvement in )]TJ
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1995;38:727-35.)]TJ
0 Tc -2.175 -1.25 Td
[(13.)-875 (Ropes MW)91.8 (, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958)]TJ
-0.00011 Tc 2.175 -1.25 Td
(Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum)Tj
T*
(Dis 1958;9:175-6.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Steinbrocker O, Batterman R. )17.7 (Therapeutic criteria in rheumatoid)]TJ
0 Tc 2.175 -1.25 Td
[(arthritis. JAMA)-220.1 (1949;140:659-62.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Larsen )54.8 (A. )54.8 (A)-220.1 (radiological method for grading the severity of rheuma-)]TJ
2.175 -1.25 Td
(toid arthritis. Scand J Rheumatol 1975;4:225-33.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an)]TJ
2.175 -1.25 Td
(articular index for the assessment of joint tenderness in patients)Tj
T*
(with rheumatoid arthritis. Q J Med 1968;37:393-406.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Ball J. Serum factor in rheumatoid arthritis agglutinating sensitised)]TJ
2.175 -1.25 Td
(sheep red cells. Lancet 1950;2:520-4.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Monson RR, Hall )54.8 (AP)110.8 (. Mortality among arthritics. J Chron Dis)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1976;29:459-67.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Koota K, Isomaki H, Mutru O. Death rate and causes of death in)]TJ
2.175 -1.25 Td
[(RA)-220.2 (patients during a period of five years. Scand J Rheumatol)]TJ
0 Tc 0 Tw T*
(1977;6:241-4.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (V)110.8 (andenbroucke JP)110.7 (, Hazevoet HM, Cats )54.8 (A. Survival and cause of)]TJ
2.175 -1.25 Td
(death in rheumatoid arthritis: a 25-year prospective followup. )Tj
T*
[(J Rheumatol 1984;1)36.8 (1:158-61.)]TJ
-2.175 -1.25 Td
[(21.)-875.1 (Prior P)110.7 (, Symmons DP)110.7 (, Scott DL, Brown R, Hawkins CF)79.7 (. Cause of)]TJ
2.175 -1.25 Td
(death in rheumatoid arthritis. Br J Rheumatol 1984;23:92-9.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (Pincus )17.7 (T)74 (, Brooks RH, Callahan LF)79.7 (. Prediction of long-term )]TJ
2.175 -1.25 Td
(mortality in patients with rheumatoid arthritis according to simple)Tj
T*
[(questionnaire and joint count measures. )54.8 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
(1994;120:26-34.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (W)79.9 (allber)17.7 (g-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular)]TJ
2.175 -1.25 Td
(morbidity and mortality in patients with seropositive rheumatoid)Tj
T*
(arthritis in Northern Sweden. J Rheumatol 1997;24:445-51.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (Kvalvik )54.8 (AG, Jones MA, Symmons DP)110.7 (. Mortality in a cohort of)]TJ
2.175 -1.25 Td
(Norwegian patients with rheumatoid arthritis followed from 1977 to)Tj
T*
(1992. Scand J Rheumatol 2000;29:29-37.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Heliovaara M, )54.8 (Aho K, Knekt P)110.7 (,)-0.1 ( )54.8 (Aromaa )54.8 (A, Maatela J, Reunanen )54.8 (A.)]TJ
2.175 -1.25 Td
[(Rheumatoid factor)39.7 (, chronic arthritis and mortality)64.8 (. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
[(1995;54:81)36.9 (1-4.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Myllykangas-Luosujarvi R, )54.8 (Aho K, Kautiainen H, Isomaki H.)]TJ
2.175 -1.25 Td
(Shortening of life span and causes of excess mortality in a )Tj
T*
(population-based series of subjects with rheumatoid arthritis. Clin)Tj
T*
(Exp Rheumatol 1995;13:149-53.)Tj
30.8875 60 Td
[(27.)-875.1 (Lindqvist E, Eberhardt K. Mortality in rheumatoid arthritis patients)]TJ
2.175 -1.25 Td
[(with disease onset in the 1980s. )54.8 (Ann Rheum Dis 1999;58:1)36.8 (1-4.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Kroot EJ, van Leeuwen MA, van Rijswijk MH, et al. No increased)]TJ
2.175 -1.25 Td
(mortality in patients with rheumatoid arthritis: up to 10 years of fol-)Tj
T*
[(low up from disease onset. )54.8 (Ann Rheum Dis 2000;59:954-8.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (W)79.9 (ard MM. Recent improvements in survival in patients with)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis: better outcomes or dif)17.7 (ferent study designs?)]TJ
T*
(Arthritis Rheum 2001;44:1467-9.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Erhardt CC, Mumford P)91.7 (A, )17.7 (V)110.8 (enables PJ, Maini RN. Factors )]TJ
2.175 -1.25 Td
(predicting a poor life prognosis in rheumatoid arthritis: an eight)Tj
T*
[(year prospective study)64.8 (. )54.8 (Ann Rheum Dis 1989;48:7-13.)]TJ
-2.175 -1.25 Td
[(31.)-875.1 (T)35 (uresson C, Jacobsson L, Ber)17.7 (gstrom U. Extra-articular rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis: prevalence and mortality)64.8 (. Rheumatology Oxford)]TJ
0 Tc 0 Tw T*
(1999;38:668-74.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (Jacobsson L)91.7 (T)74 (, )17.7 (T)35 (uresson C, Hanson RL, et al. Joint swelling as a)]TJ
2.175 -1.25 Td
(predictor of death from cardiovascular disease in a population study)Tj
T*
[(of Pima Indians. )54.8 (Arthritis Rheum 2001;44:1)36.8 (170-6.)]TJ
-2.175 -1.25 Td
[(33.)-875.1 (Kirwan J, Byron M, )17.7 (W)79.9 (att I. )17.7 (The relationship between soft tissue)]TJ
2.175 -1.25 Td
(swelling, joint space narrowing and erosive damage in hand X-rays)Tj
T*
(of patients with rheumatoid arthritis. Rheumatology Oxford)Tj
0 Tc 0 Tw T*
(2001;40:297-301.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875.1 (Ridker PM, Cushman M, Stampfer MJ, )17.7 (T)35 (racy RP)110.7 (, Hennekens CH.)]TJ
2.175 -1.25 Td
(Inflammation, aspirin, and the risk of cardiovascular disease in)Tj
T*
(apparently healthy men. N Engl J Med 1997;336:973-9.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein)]TJ
2.175 -1.25 Td
(and other markers of inflammation in the prediction of )Tj
T*
(cardiovascular disease in women. N Engl J Med 2000;342:836-43.)Tj
-2.175 -1.25 Td
[(36.)-875.1 (Ridker PM, Cushman M, Stampfer MJ, )17.7 (T)35 (racy RP)110.7 (, Hennekens CH.)]TJ
2.175 -1.25 Td
(Plasma concentration of C-reactive protein and risk of developing)Tj
T*
(peripheral vascular disease. Circulation 1998;97:425-8.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ,)]TJ
2.175 -1.25 Td
(Allen J. Plasma concentration of soluble intercellular adhesion )Tj
T*
(molecule 1 and risks of future myocardial infarction in apparently)Tj
T*
(healthy men. Lancet 1998;351:88-92.)Tj
-2.175 -1.25 Td
[(38.)-875.1 (Chehata JC, Hassell )54.8 (AB, Clarke SA, et al. Mortality in rheumatoid)]TJ
2.175 -1.25 Td
(arthritis: relationship to single and composite measures of disease)Tj
T*
[(activity)64.9 (. Rheumatology Oxford 2001;40:447-52.)]TJ
-2.175 -1.25 Td
[(39.)-875.1 (Myllykangas-Luosujarvi RA, )54.8 (Aho K, Isomaki HA. Mortality in)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis. Semin )54.8 (Arthritis Rheum 1995;25:193-202.)]TJ
-2.175 -1.25 Td
[(40.)-875.1 (Harrison BJ, Silman )54.8 (AJ, )17.7 (W)39.9 (iles NJ, Scott DG, Symmons DP)110.7 (. )17.7 (The)]TJ
2.175 -1.25 Td
(association of cigarette smoking with disease outcome in patients)Tj
T*
[(with early inflammatory polyarthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2001;44:323-30.)Tj
ET
0 0 0 0 k
/GS0 gs
104.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.631 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
37 0 obj
<>stream
8;Z\7Mc'X#%*\bO@"(VHlm!KhD3]+\+gu^KL6-40bF*YB?Wk>1429[6]4dhE:ECUr
j*,lX540%"E=&MG^+>atfe)`:ot5rEEWP>Wf=!f(0!\C;Rk,o^(723;Q$n:b>6R]O
EVisFn,ftTm=fu5e+)GLJEa@L/Rl:12[_OD;.BdRc\sCt_I;8u9<:DLBHh)EM]r0)
noY##i0\A"F!^Pg-,bS?[9g^-L1urs)]=iM[S<9Nd:qE]F5Qct@1ZCFQE$HZhmXg^sq\=,`/78r4*W-UGP0:*>3
H&ZO%NpH)fBBD3?9[HFQ8#26>1lPFS#dL;L>,5lZAi'`W^?)3,Nm#,ep#h.o][<<:
6_H%Yf9g:>9G:GYog@EXh\rWK4Uro'MF+WUdi-ga>3)/6J'6L,!(sD?BmAJ*90e/$
p.'mL`VUE#jWh[1$Y39Zf:SHU5j*8PA?jXG5A6W#iE)fb_^o9bu%B5]?nD7d3hS>Q91;)'GD)7jbauZ
[Rgcfd0AtnN>s`nK42&F?cX;CL@1;=4-XF#&:T'EkFsp!b2/_"$JL1Y^82E*Igl'qQ1BV=r.3c/"2#PRG5J1@9q1,2j+jSrdmSZNZC3)m$R_R
o7B\h]Y"-F]O#t
endstream
endobj
41 0 obj
[/Indexed/DeviceRGB 255 40 0 R]
endobj
40 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
60 0 obj
<>
endobj
72 0 obj
<>
endobj
96 0 obj
<>
endobj
112 0 obj
<>
endobj
71 0 obj
<>
endobj
88 0 obj
<>stream
H|T PTW7"4ҟo5Deт8l=*
4@C76 "͖TY@Ӵ(.!M F%1ȌV*:q'TMʚzU^zֹ{pLp'?ٸvςxzQ2^:b#qsp-rG ͖`W:h!f+rd~`UOu:;/Yr21M,{?U.|W.3Bj_BRTɓe2ϸ8Y
jYBPiL7Te1j\G(=2e?&Ay NJ,ƄS
SDU1
o|scn:`fc9`JjŰ n#8wyּyr^67wĄ}V$fi=gO>a₥>8]9VV#3"gnH6HNsH5y(5RP؆[id>~š6UtttqqG3g̴eb.Qg!(fT}C'/dM.D 6L(J؊=T1j
/._Yg/?c!X)ݒVYΒ*3*vJ|4yueLnUy~PUQ.
Sɵ_>ӯGRKH|&6 ^r^f, "Y?4pQQ StXZZOΊՓR1>tMU-v!/
<1A;}Q\x*3 \siT`g #iR{#Mjma
:]wkƨMq&1*+~KEDҷk.HkzĹv9}7hhfdO:FOE=M]MtE>I`v7p&&jNek-X*hE%?j )(H,>~|2uXw$}|JGњ^NJK5)x6||(woPP%6萏{!"dSo!a/G)YvdNHK0C
gźLӊ1M)ǻX(:Wtri.INmyF2bW?SLa?" Rr&.|p%
%7-ځ3uyDIиz.YE(h8&;,ԭƼT*#}1SUn!ŏ0WװM{$QK]8SO:Gƥm:ypN05op)Ў\SsBT ZEE6,"SޠV0AD?}5w~=
+a=.%geg%IBpt^4{c6%~^K8z%84ACi|!w,Ыfk2cCZR60N47;{2hT\&8O>ir>5%SC4I!^OM}BML
+C^2DN@4Qct{^]w
3xWi=+f0G- N5po'І~D|8o<&R49|Ku|w̦e
UZ\^
JO<h %d_/לBL>/$Vy O#Oӆx:%e5"KߎG]H!$x疾xBf;R>w~PQi